Rebate Card For Alcon’s Pataday Is More Than Meets The Eye, FDA Says
This article was originally published in The Pink Sheet Daily
Promotion is not a reminder ad since the ophthalmic’s indication is depicted graphically, a notice of violation letter contends. Citation about advertising and promotional infractions is the second in about a year for Alcon Research.
You may also be interested in...
FDA’s most recent advertising letter to Alcon about its marketing practices makes the ninth such letter sent to the ophthalmology-focused firm in roughly 10 years; this time, the Office of Prescription Drug Promotion says the Novartis unit has omitted material facts and overstated efficacy and superiority in a brochure for Pataday.
The eighth enforcement letter from FDA in a decade cites the company for unjustified claims about its seasonal allergic rhinitis drug, Patanase.